Reactivation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer
Date
2018
Editor(s)
Advisor
Supervisor
Co-Advisor
Co-Supervisor
Instructor
Citation Stats
Series
Abstract
Source Title
Clinical Cancer Research
Publisher
American Association for Cancer Research
Course
Other identifiers
Book Title
Keywords
Degree Discipline
Degree Level
Degree Name
Citation
Permalink
Published Version (Please cite this version)
Language
English